<!DOCTYPE html>
<html>
<head>

<script id="f5_cspm">
(function(){var f5_cspm={f5_p:'DJEMKDPAMMMBIEKCOPCAMMCFDPFHNDOPFHCKGECPAAPBIMBFGPOIJMFHBLIAFBEMCCEMKACFBHNPIKKCALAPGNCHABAIFOMFNKPGBAGIIEGKHAGEBBDENFGNMLGJMGOI',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}
return;}}
catch(err){return;}
setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}
f5_cspm.go();}());
</script>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - EDLUAR- zolpidem tartrate tablet</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">EDLUAR- zolpidem tartrate
tablet<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AEDLUAR%2D%20Zolpidem%20Tartrate%20Tablet%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dde965605%2D268a%2D4479%2D86f7%2D84de949cf36f%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22zolpidem%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=zolpidem"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=zolpidem"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=zolpidem[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=zolpidem/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=zolpidem/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=zolpidem/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=zolpidem[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00095&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">42447-112-01, 42447-112-03, 42447-112-10,
42447-122-01, <a class="view-more show-js" href="#">view
more</a></span>
<div class="more-codes"><span id="item-code-s"><span>42447-122-03,
42447-122-10</span></span></div>
</li>
<li><strong>Packager:</strong> Meda Pharmaceuticals</li>
</ul>
<ul class="drug-information">
<li><strong>Category:</strong> <span id="category" class=
"orangetext">HUMAN PRESCRIPTION DRUG LABEL WITH
HIGHLIGHTS</span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">CIV</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status"></span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated March 27, 2009</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=de965605-268a-4479-86f7-84de949cf36f&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=de965605-268a-4479-86f7-84de949cf36f&amp;type=pdf&amp;name=de965605-268a-4479-86f7-84de949cf36f"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=de965605-268a-4479-86f7-84de949cf36f&amp;type=zip&amp;name=EDLUAR"
target="_blank">XML</a></li>
<li class="medguide">Medication Guide: <a href=
"/dailymed/medguide.cfm?setid=de965605-268a-4479-86f7-84de949cf36f"
target="_blank">HTML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=de965605-268a-4479-86f7-84de949cf36f&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a>
<div id="Highlights" class=" Highlights toggle-content closed">
<div class="HighlightsDisclaimer">Edluarâ„¢ (zolpidem tartrate)
sublingual tablets</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Edluar (zolpidem tartrate) sublingual tablet
is indicated for the short-term treatment of insomnia characterized
by difficulties with sleep initiation. Zolpidem tartrate has been
shown to decrease sleep latency for up to 35 days in controlled
clinical studies. (<span class="Underline"><a href=
"#splSectionPLRIndicationsUsage">1</a></span>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>Adult dose: 10 mg once daily immediately before bedtime.
(<span class="Underline"><a href="#splSection1">2.1</a></span>)
Edluar sublingual tablet should be placed under the tongue, where
it will disintegrate. The tablet should not be swallowed and the
tablet should not be taken with water. (<span class=
"Underline"><a href="#splSection4">2.4</a></span>)</li>
<li>Elderly/Debilitated patients/Hepatic impairment: 5 mg once
daily immediately before bedtime. (<span class="Underline"><a href=
"#splSection2">2.2</a></span>)</li>
<li>Downward dosage adjustment may be necessary when used with CNS
depressants. (<span class="Underline"><a href=
"#splSection3">2.3</a></span>)</li>
<li>Edluar should not be administered with or immediately after a
meal. (<span class="Underline"><a href=
"#splSection4">2.4</a></span>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">5 mg and 10 mg sublingual tablets. Tablets
not scored. (<span class="Underline"><a href=
"#splSectionPLRDosageFormsStrength">3</a></span>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">Known hypersensitivity to zolpidem tartrate
or to any of the inactive ingredients in the formulation.
(<span class="Underline"><a href=
"#splSectionPLRContraindications">4</a></span>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul class="Disc">
<li>Need to evaluate for co-morbid diagnosis. Reevaluate if
insomnia persists after 7 to 10 days of use. (<span class=
"Underline"><a href="#splSection5">5.1</a></span>)</li>
<li>Severe anaphylactic and anaphylactoid reactions: angioedema and
anaphylaxis have been reported. Do not rechallenge if such
reactions occur. (<span class="Underline"><a href=
"#splSection6">5.2</a></span>)</li>
<li>Abnormal thinking, behaviour changes and complex behaviors: May
include "sleep-driving" and hallucinations. Immediately evaluate
any new onset behavioural changes. (<span class=
"Underline"><a href="#splSection7">5.3</a></span>)</li>
<li>Depression: Worsening of depression or, suicidal thinking may
occur. Prescribe the least amount feasible to avoid intentional
overdose. (<span class="Underline"><a href=
"#splSection7">5.3</a></span>, <span class="Underline"><a href=
"#splSection10">5.6</a></span>)</li>
<li>Withdrawal effects: Symptoms may occur with rapid dose
reduction or discontinuation. (<span class="Underline"><a href=
"#splSection8">5.4</a></span>, <span class="Underline"><a href=
"#splSectionPLRDependence">9.3</a></span>)</li>
<li>CNS depressant effects: Use can impair alertness and motor
coordination. If used in combination with other CNS depressants,
dose reductions may be needed due to additive effects. Do not use
with alcohol. (<span class="Underline"><a href=
"#splSection3">2.3</a></span>, <span class="Underline"><a href=
"#splSection9">5.5</a></span>)</li>
<li>Elderly/debilitated patients: Use lower dose due to impaired
motor, cognitive performance after repeated exposure, and increased
sensitivity. (<span class="Underline"><a href=
"#splSection2">2.2</a></span>, <span class="Underline"><a href=
"#splSection10">5.6</a></span>)</li>
<li>Patients with hepatic impairment, mild to moderate COPD,
impaired drug metabolism or hemodynamic responses, mild to moderate
sleep apnea: Use with caution and monitor closely. (<span class=
"Underline"><a href="#splSection10">5.6</a></span>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>Most commonly observed adverse events using zolpidem tartrate
were:</li>
</ul>
<p class="Highlighta">-Short-term (&lt;10 nights): Drowsiness,
dizziness and diarrhea;</p>
<p class="Highlighta">-Long-term (28-35 nights): Dizziness and
drugged feelings (<span class="Underline"><a href=
"#splSection11">6.1</a></span>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<ul class="Disc">
<li>CNS-depressants: Enhanced CNS-depressant effects with
combination use.</li>
<li>Use with alcohol causes additive psychomotor impairment.
(<span class="Underline"><a href="#splSection12">7.1</a></span>,
<span class="Underline"><a href=
"#splSectionPLRPharmacokinetics">12.3</a></span>)</li>
<li>Imipramine: Decreased alertness observed with combination use.
(<span class="Underline"><a href="#splSection12">7.1</a></span>,
<span class="Underline"><a href=
"#splSectionPLRPharmacokinetics">12.3</a></span>)</li>
<li>Chlorpromazine: Impaired alertness and psychomotor performance
observed with combination use. (<span class="Underline"><a href=
"#splSection12">7.1</a></span>, <span class="Underline"><a href=
"#splSectionPLRPharmacokinetics">12.3</a></span>)</li>
<li>Rifampin: Combination use decreases exposure to, and effect of
zolpidem. (<span class="Underline"><a href=
"#splSection13">7.2</a></span>, <span class="Underline"><a href=
"#splSectionPLRPharmacokinetics">12.3</a></span>)</li>
<li>Ketoconazole: Combination use increases exposure to, and effect
of zolpidem. (<span class="Underline"><a href=
"#splSection13">7.2</a></span>, <span class="Underline"><a href=
"#splSectionPLRPharmacokinetics">12.3</a></span>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC
POPULATIONS</span></h1>
<div>
<ul class="Disc">
<li>Pregnancy: Based on animal data, zolpidem may cause fetal harm.
(<span class="Underline"><a href=
"#splSectionPLRPregnancy">8.1</a></span>)</li>
<li>Nursing mothers: Zolpidem is excreted in human milk.
(<span class="Underline"><a href=
"#splSectionPLRNursing">8.3</a></span>)</li>
<li>Pediatric use: Safety and effectiveness not established.
Hallucinations (incidence rate 7.4%) and other psychiatric and/or
nervous system adverse reactions were observed frequently in a
study of pediatric patients with Attention-Deficit/Hyperactivity
Disorder. (<span class="Underline"><a href=
"#splSection10">5.6</a></span>, <span class="Underline"><a href=
"#splSectionPLRPediatric">8.4</a></span>)</li>
</ul>
</div>
</div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING
INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2009</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a>
<div id="Index" class=" Index toggle-content closed">
<h1><a href="#section-2" class="toc">1 INDICATIONS AND
USAGE</a></h1>
<h1><a href="#section-3" class="toc">2 DOSAGE AND
ADMINISTRATION</a></h1>
<h2><a href="#section-3.1" class="toc">2.1 Dosage in
adults</a></h2>
<h2><a href="#section-3.2" class="toc">2.2 Special
populations</a></h2>
<h2><a href="#section-3.3" class="toc">2.3 Use with CNS
depressants</a></h2>
<h2><a href="#section-3.4" class="toc">2.4 Administration</a></h2>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND
STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5 WARNINGS AND
PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1 Need to evaluate for
co-morbid diagnoses</a></h2>
<h2><a href="#section-6.2" class="toc">5.2 Severe anaphylactic and
anaphylactoid reactions</a></h2>
<h2><a href="#section-6.3" class="toc">5.3 Abnormal thinking and
behavioral changes</a></h2>
<h2><a href="#section-6.4" class="toc">5.4 Withdrawal
effects</a></h2>
<h2><a href="#section-6.5" class="toc">5.5 CNS depressant
effects</a></h2>
<h2><a href="#section-6.6" class="toc">5.6 Special
populations</a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1 Clinical trials
experience</a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-8.1" class="toc">7.1 CNS-active
drugs</a></h2>
<h2><a href="#section-8.2" class="toc">7.2 Drugs that affect drug
metabolism via cytochrome P450</a></h2>
<h2><a href="#section-8.3" class="toc">7.3 Drug-laboratory test
interactions</a></h2>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC
POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.2 Labor and
delivery</a></h2>
<h2><a href="#section-9.3" class="toc">8.3 Nursing mothers</a></h2>
<h2><a href="#section-9.4" class="toc">8.4 Pediatric use</a></h2>
<h2><a href="#section-9.5" class="toc">8.5 Geriatric use</a></h2>
<h1><a href="#section-10" class="toc">9 DRUG ABUSE AND
DEPENDENCE</a></h1>
<h2><a href="#section-10.1" class="toc">9.1 Controlled
substance</a></h2>
<h2><a href="#section-10.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-10.3" class="toc">9.3 Dependence</a></h2>
<h1><a href="#section-11" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-11.1" class="toc">10.1 Signs and
symptoms</a></h2>
<h2><a href="#section-11.2" class="toc">10.2 Recommended
treatment</a></h2>
<h1><a href="#section-12" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-13" class="toc">12 CLINICAL
PHARMACOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">12.1 Mechanism of
action</a></h2>
<h2><a href="#section-13.2" class="toc">12.3
Pharmacokinetics</a></h2>
<h1><a href="#section-14" class="toc">13 NONCLINICAL
TOXICOLOGY</a></h1>
<h2><a href="#section-14.1" class="toc">13.1 Carcinogenesis,
mutagenesis, impairment of fertility</a></h2>
<h1><a href="#section-15" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-15.1" class="toc">14.1 Chronic
insomnia</a></h2>
<h2><a href="#section-15.2" class="toc">14.2 Transient
insomnia</a></h2>
<h2><a href="#section-15.3" class="toc">14.3 Studies pertinent to
safety concerns for sedative/hypnotic drugs</a></h2>
<h1><a href="#section-16" class="toc">16 HOW SUPPLIED/STORAGE AND
HANDLING</a></h1>
<h2><a href="#section-16.1" class="toc">16.1 How supplied</a></h2>
<h2><a href="#section-16.2" class="toc">16.2 Storage and
handling</a></h2>
<h1><a href="#section-17" class="toc">17 PATIENT COUNSELING
INFORMATION</a></h1>
<h2><a href="#section-17.1" class="toc">17.1 Severe anaphylactic
and anaphylactoid reactions</a></h2>
<h2><a href="#section-17.2" class="toc">17.2 Sleep-driving and
other complex behaviors</a></h2>
<h2><a href="#section-17.3" class="toc">17.3 Administration
instructions</a></h2>
<h2><a href="#section-17.4" class="toc">17.4 Medication
guide</a></h2>
<dl class="Footnote">
<dt><a name="footnote-content" href="#footnote-reference-content"
id="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing
information are not listed.</dd>
</dl>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">1 INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name="splSectionPLRIndicationsUsage" id=
"splSectionPLRIndicationsUsage"></a> <a name="section-2" id=
"section-2"></a>
<p class="First">Edluar (zolpidem tartrate) sublingual tablet is
indicated for the short-term treatment of insomnia characterized by
difficulties with sleep initiation.</p>
<p>The clinical trials performed with Zolpidem tartrate in support
of efficacy were 4-5 weeks in duration with the final formal
assessments of sleep latency performed at the end of treatment
<span class="Italics">[see Clinical Studies</span> (<span class=
"Underline"><a href=
"#splSectionPLRClinicalStudies">14</a></span>)<span class=
"Italics">].</span></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">2 DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name="splSectionPLRDosageAdministration" id=
"splSectionPLRDosageAdministration"></a> <a name="section-3" id=
"section-3"></a>
<p class="First">The dose of Edluar should be individualized.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection1" id="splSection1"></a> <a name="section-3.1" id=
"section-3.1"></a>
<h2>2.1 Dosage in adults</h2>
<p class="First">The recommended dose for Edluar for adults is 10
mg once daily immediately before bedtime. The total Edluar daily
dose should not exceed 10 mg.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection2" id="splSection2"></a> <a name="section-3.2" id=
"section-3.2"></a>
<h2>2.2 Special populations</h2>
<p class="First">Elderly or debilitated patients may be especially
sensitive to the effects of zolpidem tartrate. Patients with
hepatic insufficiency do not clear the drug as rapidly as normal
subjects. The recommended dose of Edluar in both of these patient
populations is 5 mg once daily immediately before bedtime
<span class="Italics">[see Warnings and Precautions</span>
(<span class="Underline"><a href=
"#splSection10">5.6</a></span>)<span class="Italics">].</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection3" id="splSection3"></a> <a name="section-3.3" id=
"section-3.3"></a>
<h2>2.3 Use with CNS depressants</h2>
<p class="First">Dosage adjustment may be necessary when Edluar is
combined with other CNS-depressant drugs because of the potentially
additive effects <span class="Italics">[see Warnings and
Precautions</span> (<span class="Underline"><a href=
"#splSection9">5.5</a></span>)<span class="Italics">].</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection4" id="splSection4"></a> <a name="section-3.4" id=
"section-3.4"></a>
<h2>2.4 Administration</h2>
<p class="First">The effect of Edluar may be slowed by ingestion
with or immediately after a meal. Edluar should not be given with
or immediately after a meal.</p>
<p>Edluar sublingual tablet should be placed under the tongue,
where it will disintegrate. The tablet should not be swallowed and
the tablet should not be taken with water.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43678-2"><a name="splSectionPLRDosageFormsStrength" id=
"splSectionPLRDosageFormsStrength"></a> <a name="section-4" id=
"section-4"></a>
<p class="First">Edluar is available in 5 mg and 10 mg strength
tablets for sublingual administration. Tablets are <span class=
"Underline">not</span> scored.</p>
<p>Edluar 5 mg sublingual tablets are round white, flat-faced,
bevel-edged, with debossed <img src=
"image.cfm?setid=de965605-268a-4479-86f7-84de949cf36f&amp;name=zolpidem-tartrate-02.jpg"
alt="Image from Drug Label Content"> on one side.</p>
<p>Edluar 10 mg sublingual tablets are round white, flat-faced,
bevel-edged, with debossed <img src=
"image.cfm?setid=de965605-268a-4479-86f7-84de949cf36f&amp;name=zolpidem-tartrate-03.jpg"
alt="Image from Drug Label Content"> on one side.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">4 CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name="splSectionPLRContraindications" id=
"splSectionPLRContraindications"></a> <a name="section-5" id=
"section-5"></a>
<p class="First">Edluar is contraindicated in patients with known
hypersensitivity to zolpidem tartrate or to any of the inactive
ingredients in the formulation. Observed reactions include
anaphylaxis and angioedema <span class="Italics">[see Warnings and
Precautions</span> (<span class="Underline"><a href=
"#splSection6">5.2</a></span>) <span class="Italics">and
Description</span> (<span class="Underline"><a href=
"#splSectionPLRDescription">11</a></span>)<span class=
"Italics">].</span></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">5 WARNINGS AND PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43685-7"><a name="splSectionPLRWarnings" id=
"splSectionPLRWarnings"></a> <a name="section-6" id=
"section-6"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection5" id="splSection5"></a> <a name="section-6.1" id=
"section-6.1"></a>
<h2>5.1 Need to evaluate for co-morbid diagnoses</h2>
<p class="First">Because sleep disturbances may be the presenting
manifestation of a physical and/or psychiatric disorder,
symptomatic treatment of insomnia should be initiated only after a
careful evaluation of the patient. <span class="Bold">The failure
of insomnia to remit after 7 to 10 days of treatment may indicate
the presence of a primary psychiatric and/or medical illness that
should be evaluated.</span> Worsening of insomnia or the emergence
of new thinking or behavior abnormalities may be the consequence of
an unrecognized psychiatric or physical disorder. Such findings
have emerged during the course of treatment with sedative/hypnotic
drugs, including zolpidem tartrate.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection6" id="splSection6"></a> <a name="section-6.2" id=
"section-6.2"></a>
<h2>5.2 Severe anaphylactic and anaphylactoid reactions</h2>
<p class="First">Rare cases of angioedema involving the tongue,
glottis or larynx have been reported in patients after taking the
first or subsequent doses of sedative-hypnotics, including zolpidem
tartrate. Some patients have had additional symptoms such as
dyspnea, throat closing or nausea and vomiting that suggest
anaphylaxis. Some patients have required medical therapy in the
emergency department. If angioedema involves the throat, glottis or
larynx, airway obstruction may occur and be fatal. Patients who
develop angioedema after treatment with Edluar should not be
rechallenged with the drug.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection7" id="splSection7"></a> <a name="section-6.3" id=
"section-6.3"></a>
<h2>5.3 Abnormal thinking and behavioral changes</h2>
<p class="First">A variety of abnormal thinking and behavior
changes have been reported to occur in association with the use of
sedative/hypnotics. Some of these changes may be characterized by
decreased inhibition (e.g. aggressiveness and extroversion that
seemed out of character), similar to effects produced by alcohol
and other CNS depressants. Visual and auditory hallucinations have
been reported as well as behavioral changes such as bizarre
behavior, agitation and depersonalization. In controlled trials,
&lt;1% of adults with insomnia who received zolpidem tartrate
reported hallucinations. In a clinical trial, 7.4% of pediatric
patients with insomnia associated with
attention-deficit/hyperactivity disorder (ADHD), who received
zolpidem reported hallucinations <span class="Italics">[see Use in
Specific Populations</span> (<span class="Underline"><a href=
"#splSectionPLRPediatric">8.4</a></span>)<span class=
"Italics">].</span></p>
<p>Complex behaviors such as "sleep-driving" (i.e., driving while
not fully awake after ingestion of a sedative-hypnotic, with
amnesia for the event) have been reported with sedative-hypnotics,
including zolpidem tartrate. These events can occur in
sedative-hypnotic-naive as well as in sedative-hypnotic-experienced
persons. Although behaviors such as "sleep-driving" may occur with
Edluar alone at therapeutic doses, the use of alcohol and other CNS
depressants with Edluar appears to increase the risk of such
behaviors, as does the use of Edluar at doses exceeding the maximum
recommended dose. Due to the risk to the patient and the community,
discontinuation of Edluar should be strongly considered for
patients who report a "sleep-driving" episode. Other complex
behaviors (e.g., preparing and eating food, making phone calls, or
having sex) have been reported in patients who are not fully awake
after taking a sedative-hypnotic. As with "sleep-driving", patients
usually do not remember these events. Amnesia, anxiety and other
neuro-psychiatric symptoms may occur unpredictably.</p>
<p>In primarily depressed patients, worsening of depression,
including suicidal thoughts and actions (including completed
suicides), has been reported in association with the use of
sedative/hypnotics.</p>
<p>It can rarely be determined with certainty whether a particular
instance of the abnormal behaviors listed above is drug-induced,
spontaneous in origin, or a result of an underlying psychiatric or
physical disorder. Nonetheless, the emergence of any new behavioral
sign or symptom of concern requires careful and immediate
evaluation.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection8" id="splSection8"></a> <a name="section-6.4" id=
"section-6.4"></a>
<h2>5.4 Withdrawal effects</h2>
<p class="First">Following rapid dose decrease or abrupt
discontinuation of sedative/hypnotics, there have been reports of
signs and symptoms similar to those associated with withdrawal from
other CNS-depressant drugs <span class="Italics">[see Drug Abuse
and Dependence</span> (<span class="Underline"><a href=
"#splSectionPLRDrugAbuse">9</a></span>)<span class=
"Italics">].</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection9" id="splSection9"></a> <a name="section-6.5" id=
"section-6.5"></a>
<h2>5.5 CNS depressant effects</h2>
<p class="First">Edluar, like other sedative/hypnotic drugs, has
CNS-depressant effects. <span class="Underline">Due to the rapid
onset of action, Edluar should be ingested immediately prior to
going to bed.</span> Patients should be cautioned against engaging
in hazardous occupations requiring complete mental alertness or
motor coordination such as operating machinery or driving a motor
vehicle after ingesting the drug, including potential impairment of
the performance of such activities that may occur the day following
ingestion of Edluar. Zolpidem tartrate showed additive effects when
combined with alcohol and should not be taken with alcohol.
Patients should also be cautioned about possible combined effects
with other CNS-depressant drugs. Dosage adjustments of Edluar may
be necessary when Edluar is administered with such agents because
of the potentially additive effects.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection10" id="splSection10"></a> <a name="section-6.6" id=
"section-6.6"></a>
<h2>5.6 Special populations</h2>
<p class="First"><span class="Bold Italics">Use in the elderly
and/or debilitated patients:</span></p>
<p>Impaired motor and/or cognitive performance after repeated
exposure or unusual sensitivity to sedative/hypnotic drugs is a
concern in the treatment of elderly and/or debilitated patients.
Therefore, the recommended Edluar dosage is 5 mg in the elderly
and/or debilitated patients <span class="Italics">[see Dosage and
Administration</span> (<span class="Underline"><a href=
"#splSection2">2.2</a></span>) <span class="Italics">and Geriatric
Use</span> (<span class="Underline"><a href=
"#splSectionPLRGeriatric">8.5</a></span>)<span class=
"Italics">]</span> to decrease the possibility of side effects.
These patients should be closely monitored.</p>
<p><span class="Bold Italics">Use in patients with concomitant
illness:</span></p>
<p>Clinical experience with zolpidem tartrate in patients with
concomitant systemic illness is limited. Caution is advisable in
using Edluar in patients with diseases or conditions that could
affect metabolism or hemodynamic responses. Although studies did
not reveal respiratory depressant effects at hypnotic doses of
zolpidem tartrate in normal subjects or in patients with mild to
moderate chronic obstructive pulmonary disease (COPD), a reduction
in the Total Arousal Index together with a reduction in lowest
oxygen saturation and increase in the times of oxygen desaturation
below 80% and 90% was observed in patients with mild-to-moderate
sleep apnea when treated with zolpidem tartrate (10 mg) when
compared to placebo. Since sedative/hypnotics have the capacity to
depress respiratory drive, precautions should be taken if Edluar is
prescribed to patients with compromised respiratory function.
Edluar should be used with caution in patients with sleep apnea
syndrome or myasthenia gravis. Post-marketing reports of
respiratory insufficiency following treatment with zolpidem
tartrate, most of which involved patients with pre-existing
respiratory impairment, have been received.</p>
<p>Data in end-stage renal failure patients repeatedly treated with
zolpidem tartrate did not demonstrate drug accumulation or
alterations in pharmacokinetic parameters. No dosage adjustment of
Edluar in renally impaired patients is required; however, these
patients should be closely monitored <span class="Italics">[see
Clinical Pharmacology</span> (<span class="Underline"><a href=
"#splSectionPLRPharmacokinetics">12.3</a></span>)<span class=
"Italics">].</span></p>
<p>A study in subjects with hepatic impairment treated with
zolpidem tartrate did reveal prolonged elimination in this group;
therefore, treatment with Edluar should be initiated with 5 mg in
patients with hepatic compromise, and they should be closely
monitored <span class="Italics">[see Dosage and
Administration</span> (<span class="Underline"><a href=
"#splSection2">2.2</a></span>) <span class="Italics">and Clinical
Pharmacology</span> (<span class="Underline"><a href=
"#splSectionPLRPharmacokinetics">12.3</a></span>)<span class=
"Italics">].</span></p>
<p><span class="Bold Italics">Use in patients with
depression:</span></p>
<p>As with other sedative/hypnotic drugs, Edluar should be
administered with caution to patients exhibiting signs or symptoms
of depression. Suicidal tendencies may be present in such patients
and protective measures may be required. Intentional over-dosage is
more common in this group of patients; therefore, the least amount
of drug that is feasible should be prescribed for the patient at
any one time.</p>
<p><span class="Bold Italics">Pediatric patients:</span></p>
<p>Edluar is not recommended for use in children. Safety and
effectiveness of Edluar have not been established in pediatric
patients below the age of 18. In an 8-week study in pediatric
patients (aged 6-17 years) with insomnia associated with ADHD, an
oral solution of zolpidem did not decrease sleep latency compared
to placebo. Hallucinations were reported in 7.4% of the pediatric
patients who received zolpidem; none of the pediatric patients who
received placebo reported hallucinations <span class="Italics">[see
Use in Specific Populations</span> (<span class=
"Underline"><a href="#splSectionPLRPediatric">8.4</a></span>)<span class="Italics">].</span></p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">6 ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name="splSectionPLRAdverseReactions" id=
"splSectionPLRAdverseReactions"></a> <a name="section-7" id=
"section-7"></a>
<p class="First">The following serious adverse reactions are
discussed in greater detail in other sections of the labeling:</p>
<ul class="Disc">
<li>Serious anaphylactic and anaphylactoid reactions <span class=
"Italics">[see Warnings and Precautions</span> (<span class=
"Underline"><a href="#splSection6">5.2</a></span>)<span class=
"Italics">].</span></li>
<li>Abnormal thinking and behavior, complex behaviors <span class=
"Italics">[see Warnings and Precautions</span> (<span class=
"Underline"><a href="#splSection7">5.3</a></span>)<span class=
"Italics">].</span></li>
<li>Withdrawal effects <span class="Italics">[see Warnings and
Precautions</span> (<span class="Underline"><a href=
"#splSection8">5.4</a></span>)<span class="Italics">].</span></li>
<li>CNS-depressant effects <span class="Italics">[see Warnings and
Precautions</span> (<span class="Underline"><a href=
"#splSection10">5.5</a></span>)<span class="Italics">].</span></li>
</ul>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection11" id="splSection11"></a> <a name="section-7.1" id=
"section-7.1"></a>
<h2>6.1 Clinical trials experience</h2>
<p class="First">Because clinical trials are conducted under widely
varying conditions, adverse reaction rates observed in the clinical
trials of a drug cannot be directly compared to rates in the
clinical trials of another drug and may not reflect the rates
observed in practice. The adverse reaction information from
clinical trials does, however, provide a basis for identifying the
adverse events that appear to be related to drug use and for
approximating incidence rates.</p>
<p><span class="Bold Italics">Associated with discontinuation of
treatment:</span></p>
<p>Approximately 4% of 1,701 patients who received zolpidem
tartrate at all doses (1.25 to 90 mg) in U.S. premarketing clinical
trials discontinued treatment because of an adverse reaction.
Reactions most commonly associated with discontinuation from U.S.
trials were daytime drowsiness (0.5%), dizziness (0.4%), headache
(0.5%), nausea (0.6%), and vomiting (0.5%).</p>
<p>Approximately 4% of 1,959 patients who received zolpidem
tartrate at all doses (1 to 50 mg) in similar foreign trials
discontinued treatment because of an adverse reaction. Reactions
most commonly associated with discontinuation from these trials
were daytime drowsiness (1.1%), dizziness/vertigo (0.8%), amnesia
(0.5%), nausea (0.5%), headache (0.4%), and falls (0.4%).</p>
<p>Data from a clinical study in which selective serotonin reuptake
inhibitor (SSRI)-treated patients were given zolpidem tartrate
revealed that four of the seven discontinuations during
double-blind treatment with zolpidem (n=95) were associated with
impaired concentration, continuing or aggravated depression, and
manic reaction; one patient treated with placebo (n=97) was
discontinued after an attempted suicide.</p>
<p><span class="Bold Italics">Most commonly observed adverse
reactions in controlled trials:</span></p>
<p>During short-term treatment (up to 10 nights) with zolpidem
tartrate at doses up to 10 mg, the most commonly observed adverse
reactions associated with the use of zolpidem and seen at
statistically significant differences from placebo-treated patients
were drowsiness (reported by 2% of zolpidem patients), dizziness
(1%), and diarrhea (1%). During longer-term treatment (28 to 35
nights) with zolpidem tartrate at doses up to 10 mg, the most
commonly observed adverse reactions associated with the use of
zolpidem and seen at statistically significant differences from
placebo-treated patients were dizziness (5%) and drugged feelings
(3%).</p>
<p><span class="Bold Italics">Adverse reactions observed at an
incidence of â‰¥1% in controlled trials</span><span class=
"Bold">:</span></p>
<p>The following tables enumerate treatment-emergent adverse event
frequencies that were observed at an incidence equal to 1% or
greater among patients with insomnia who received zolpidem tartrate
and at a greater incidence than placebo in U.S. placebo-controlled
trials. Events reported by investigators were classified utilizing
a modified World Health Organization (WHO) dictionary of preferred
terms for the purpose of establishing event frequencies. The
prescriber should be aware that these figures cannot be used to
predict the incidence of side effects in the course of usual
medical practice, in which patient characteristics and other
factors differ from those that prevailed in these clinical trials.
Similarly, the cited frequencies cannot be compared with figures
obtained from other clinical investigators involving related drug
products and uses, since each group of drug trials is conducted
under a different set of conditions. However, the cited figures
provide the physician with a basis for estimating the relative
contribution of drug and nondrug factors to the incidence of side
effects in the population studied.</p>
<p>The following table was derived from a pool of 11
placebo-controlled short-term U.S. efficacy trials involving
zolpidem in doses ranging from 1.25 to 20 mg. The table is limited
to data from doses up to and including 10 mg, the highest dose
recommended for use.</p>
<div class="scrollingtable">
<table width="80%">
<caption><span>TABLE 1: Incidence of Treatment-Emergent Adverse
Experiences in Placebo-Controlled Clinical Trials with zolpidem
tartrate lasting up to 10 nights (Percentage of patients
reporting)</span></caption>
<colgroup>
<col align="left" width="33%">
<col align="center" width="33%">
<col align="center" width="33%"></colgroup>
<thead>
<tr class="First Last">
<th class="Botrule Lrule Rrule" align="left">Body System/<br>
Adverse Event*</th>
<th class="Botrule Lrule Rrule" align="center">Zolpidem
tartrate<br>
(â‰¤ 10 mg)<br>
(n=685)</th>
<th class="Botrule Lrule Rrule" align="center">Placebo<br>
<br>
(n=473)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last">
<td align="left" colspan="3">*Reactions reported by at least 1% of
patients treated with oral zolpidem and at a greater frequency than
placebo.</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"><span class=
"Bold">Central and Peripheral Nervous System</span></td>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Headache</td>
<td class="Botrule Lrule Rrule" align="center">7</td>
<td class="Botrule Lrule Rrule" align="center">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Drowsiness</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
<td class="Botrule Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Dizziness</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
<td class="Botrule Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class=
"Bold">Gastrointestinal System</span></td>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">Diarrhea</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
<td class="Botrule Lrule Rrule" align="center">-</td>
</tr>
</tbody>
</table>
</div>
<p>The following table was derived from a pool of three
placebo-controlled long-term efficacy trials involving oral
zolpidem. These trials involved patients with chronic insomnia who
were treated for 28 to 35 nights with zolpidem at doses of 5, 10,
or 15 mg. The table is limited to data from doses up to and
including 10 mg, the highest dose recommended for use. The table
includes only adverse events occurring at an incidence of at least
1% for zolpidem patients.</p>
<div class="scrollingtable">
<table width="80%">
<caption><span>TABLE 2: Incidence of Treatment-Emergent Adverse
Experiences in Placebo-Controlled Clinical Trials with zolpidem
tartrate lasting up to 35 nights (Percentage of patients
reporting)</span></caption>
<colgroup>
<col align="left" width="33%">
<col align="center" width="33%">
<col align="center" width="33%"></colgroup>
<thead>
<tr class="First Last">
<th class="Botrule Lrule Rrule" align="left">Body System/<br>
Adverse Event*</th>
<th class="Botrule Lrule Rrule" align="center">Zolpidem
tartrate<br>
(â‰¤ 10 mg)<br>
(n=152)</th>
<th class="Botrule Lrule Rrule" align="center">Placebo<br>
(n=161)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last">
<td align="left" colspan="3">*Reactions reported by at least 1% of
patients treated with oral zolpidem and at a greater frequency than
placebo.</td>
</tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"><span class=
"Bold">Autonomic Nervous System</span></td>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Dry mouth</td>
<td class="Botrule Lrule Rrule" align="center">3</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class=
"Bold">Body as a Whole</span></td>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Allergy</td>
<td class="Botrule Lrule Rrule" align="center">4</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Back pain</td>
<td class="Botrule Lrule Rrule" align="center">3</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Influenza-like
symptoms</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
<td class="Botrule Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Chest pain</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
<td class="Botrule Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class=
"Bold">Cardiovascular System</span></td>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Palpitation</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
<td class="Botrule Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class=
"Bold">Central and Peripheral Nervous System</span></td>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Drowsiness</td>
<td class="Botrule Lrule Rrule" align="center">8</td>
<td class="Botrule Lrule Rrule" align="center">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Dizziness</td>
<td class="Botrule Lrule Rrule" align="center">5</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Lethargy</td>
<td class="Botrule Lrule Rrule" align="center">3</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Drugged feeling</td>
<td class="Botrule Lrule Rrule" align="center">3</td>
<td class="Botrule Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Lightheadedness</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Depression</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Abnormal dreams</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
<td class="Botrule Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Amnesia</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
<td class="Botrule Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Sleep disorder</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
<td class="Botrule Lrule Rrule" align="center">-</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class=
"Bold">Gastrointestinal System</span></td>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Diarrhea</td>
<td class="Botrule Lrule Rrule" align="center">3</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Abdominal pain</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Constipation</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class=
"Bold">Respiratory System</span></td>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Sinusitis</td>
<td class="Botrule Lrule Rrule" align="center">4</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">Pharyngitis</td>
<td class="Botrule Lrule Rrule" align="center">3</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class=
"Bold">Skin and Appendages</span></td>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Lrule Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">Rash</td>
<td class="Botrule Lrule Rrule" align="center">2</td>
<td class="Botrule Lrule Rrule" align="center">1</td>
</tr>
</tbody>
</table>
</div>
<p><span class="Bold Italics">Dose relationship for adverse
reactions associated with oral zolpidem:</span></p>
<p>There is evidence from dose comparison trials suggesting a dose
relationship for many of the adverse reactions associated with oral
zolpidem use, particularly for certain CNS and gastrointestinal
adverse events.</p>
<p><span class="Bold Italics">Oral tissue-related adverse reactions
to Edluar:</span></p>
<p>The effect of chronic daily administration of Edluar on oral
tissue was evaluated in a 60-day open-label study in 60 insomniac
patients. One patient developed transient sublingual erythema, and
another transient paresthesia of the tongue.</p>
<p><span class="Bold Italics">Adverse event incidence across the
entire preapproval oral zolpidem database:</span> Zolpidem was
administered to 3,660 subjects in clinical trials throughout the
U.S., Canada, and Europe. Treatment-emergent adverse events
associated with clinical trial participation were recorded by
clinical investigators using terminology of their own choosing. To
provide a meaningful estimate of the proportion of individuals
experiencing treatment-emergent adverse events, similar types of
untoward events were grouped into a smaller number of standardized
event categories and classified utilizing a modified World Health
Organization (WHO) dictionary of preferred terms.</p>
<p>The frequencies presented, therefore, represent the proportions
of the 3,660 individuals exposed to zolpidem, at all doses, who
experienced an event of the type cited on at least one occasion
while receiving zolpidem. All reported treatment-emergent adverse
events are included, except those already listed in the table above
of adverse events in placebo-controlled studies, those coding terms
that are so general as to be uninformative, and those events where
a drug cause was remote. It is important to emphasize that,
although the events reported did occur during treatment with
zolpidem, they were not necessarily caused by it.</p>
<p>Adverse events are further classified within body system
categories and enumerated in order of decreasing frequency using
the following definitions: frequent adverse events are defined as
those occurring in greater than 1/100 subjects; infrequent adverse
events are those occurring in 1/100 to 1/1,000 patients; rare
events are those occurring in less than 1/1,000 patients.</p>
<p><span class="Italics">Autonomic nervous system:</span>
Infrequent: increased sweating, pallor, postural hypotension,
syncope. Rare: abnormal accommodation, altered saliva, flushing,
glaucoma, hypotension, impotence, increased saliva, tenesmus.</p>
<p><span class="Italics">Body as a whole:</span> Frequent:
asthenia. Infrequent: edema, falling, fever, malaise, trauma.</p>
<p>Rare: allergic reaction, allergy aggravated, anaphylactic shock,
face edema, hot flashes, increased ESR, pain, restless legs,
rigors, tolerance increased, weight decrease.</p>
<p><span class="Italics">Cardiovascular system:</span> Infrequent:
cerebrovascular disorder, hypertension, tachycardia.</p>
<p>Rare: angina pectoris, arrhythmia, arteritis, circulatory
failure, extrasystoles, hypertension aggravated, myocardial
infarction, phlebitis, pulmonary embolism, pulmonary edema,
varicose veins, ventricular tachycardia.</p>
<p><span class="Italics">Central and peripheral nervous
system:</span> Frequent: ataxia, confusion, euphoria, headache,
insomnia, vertigo. Infrequent: agitation, anxiety, decreased
cognition, detached, difficulty concentrating, dysarthria,
emotional lability, hallucination, hypoesthesia, illusion, leg
cramps, migraine, nervousness, paresthesia, sleeping (after daytime
dosing), speech disorder, stupor, tremor. Rare: abnormal gait,
abnormal thinking, aggressive reaction, apathy, appetite increased,
decreased libido, delusion, dementia, depersonalization, dysphasia,
feeling strange, hypokinesia, hypotonia, hysteria, intoxicated
feeling, manic reaction, neuralgia, neuritis, neuropathy, neurosis,
panic attacks, paresis, personality disorder, somnambulism, suicide
attempts, tetany, yawning.</p>
<p><span class="Italics">Gastrointestinal system:</span> Frequent:
dyspepsia, hiccup, nausea. Infrequent: anorexia, constipation,
dysphagia, flatulence, gastroenteritis, vomiting. Rare: enteritis,
eructation, esophagospasm, gastritis, hemorrhoids, intestinal
obstruction, rectal hemorrhage, tooth caries.</p>
<p><span class="Italics">Hematologic and lymphatic system:</span>
Rare: anemia, hyperhemoglobinemia, leukopenia, lymphadenopathy,
macrocytic anemia, purpura, thrombosis.</p>
<p><span class="Italics">Immunologic system:</span> Infrequent:
infection. Rare: abscess herpes simplex herpes zoster, otitis
externa, otitis media.</p>
<p><span class="Italics">Liver and biliary system:</span>
Infrequent: abnormal hepatic function, increased SGPT. Rare:
bilirubinemia, increased SGOT.</p>
<p><span class="Italics">Metabolic and nutritional:</span>
Infrequent: hyperglycemia, thirst. Rare: gout, hypercholesteremia,
hyperlipidemia, increased alkaline phosphatase, increased BUN,
periorbital edema.</p>
<p><span class="Italics">Musculoskeletal system:</span> Frequent:
arthralgia, myalgia. Infrequent: arthritis. Rare: arthrosis, muscle
weakness, sciatica, tendinitis.</p>
<p><span class="Italics">Reproductive system:</span> Infrequent:
menstrual disorder, vaginitis. Rare: breast fibroadenosis, breast
neoplasm, breast pain.</p>
<p><span class="Italics">Respiratory system:</span> Frequent: upper
respiratory infection. Infrequent: bronchitis, coughing, dyspnea,
rhinitis. Rare: bronchospasm, epistaxis, hypoxia, laryngitis,
pneumonia.</p>
<p><span class="Italics">Skin and appendages:</span> Infrequent:
pruritus. Rare: acne, bullous eruption, dermatitis, furunculosis,
injection-site inflammation, photosensitivity reaction,
urticaria.</p>
<p><span class="Italics">Special senses:</span> Frequent: diplopia,
vision abnormal. Infrequent: eye irritation, eye pain, scleritis,
taste perversion, tinnitus. Rare: conjunctivitis, corneal
ulceration, lacrimation abnormal, parosmia, photopsia.</p>
<p><span class="Italics">Urogenital system:</span> Infrequent:
urinary tract infection. Infrequent: cystitis, urinary
incontinence. Rare: acute renal failure, dysuria, micturition
frequency, nocturia, polyuria, pyelonephritis, renal pain, urinary
retention.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">7 DRUG INTERACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34073-7"><a name="splSectionPLRDrugInteract" id=
"splSectionPLRDrugInteract"></a> <a name="section-8" id=
"section-8"></a>
<p class="First">For details of drug interactions, please refer to
Clinical Pharmacology (<span class="Underline"><a href=
"#splSectionPLRPharmacokinetics">12.3</a></span>).</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection12" id="splSection12"></a> <a name="section-8.1" id=
"section-8.1"></a>
<h2>7.1 CNS-active drugs</h2>
<p class="First">Any drug with CNS-depressant effects could
potentially enhance the CNS-depressant effects of zolpidem.</p>
<p>Imipramine in combination with zolpidem produced an additive
effect of decreased alertness. Similarly, chlorpromazine in
combination with zolpidem produced an additive effect of decreased
alertness and psychomotor performance. These drugs did not show any
significant pharmacokinetic interaction.</p>
<p>A study involving haloperidol and zolpidem revealed no effect of
haloperidol on the pharmacokinetics or pharmacodynamics of
zolpidem. The lack of a drug interaction following single-dose
administration does not predict a lack following chronic
administration.</p>
<p>An additive effect on psychomotor performance between alcohol
and oral zolpidem was demonstrated <span class="Italics">[see
Warnings and Precautions: CNS depressant effects</span>
(<span class="Underline"><a href=
"#splSection9">5.5</a></span>)<span class="Italics">].</span>
Concomitant administration of zolpidem and sertraline increased
zolpidem C<span class="Sub">max</span> (43%) and decreased
T<span class="Sub">max</span> (53%), whether or not these changes
alter the pharmacodynamic effect of zolpidem is unknown.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection13" id="splSection13"></a> <a name="section-8.2" id=
"section-8.2"></a>
<h2>7.2 Drugs that affect drug metabolism via cytochrome P450</h2>
<p class="First">Some compounds known to inhibit CYP3A may increase
exposure to zolpidem. The effect of inhibitors of other P450
enzymes has not been carefully evaluated.</p>
<p>Co-administration of multiple doses of rifampin and a single
dose of zolpidem tartrate (20 mg) given 17 hours after the last
dose of rifampin showed significant reductions of the AUC (73%),
C<span class="Sub">max</span> (58%), and T<span class=
"Sub">1/2</span> (36%) of zolpidem together with significant
reductions in the pharmacodynamic effects of zolpidem tartrate.</p>
<p>Co-administration of a single dose of zolpidem tartrate with 4
doses of ketoconazole, a potent CYP3A4 inhibitor increased
C<span class="Sub">max</span> of zolpidem (30%) and the total AUC
of zolpidem (70%) compared to zolpidem alone and prolonged the
elimination half-life (30%) along with an increase in the
pharmacodynamic effects of zolpidem. Consideration should be given
to using a lower dose of zolpidem when ketoconazole and zolpidem
are given together. Patients should be advised that use of Edluar
with ketoconazole may enhance the sedative effects.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection14" id="splSection14"></a> <a name="section-8.3" id=
"section-8.3"></a>
<h2>7.3 Drug-laboratory test interactions</h2>
<p class="First">Zolpidem is not known to interfere with commonly
employed clinical laboratory tests. In addition, clinical data
indicate that zolpidem does not cross-react with benzodiazepines,
opiates, barbiturates, cocaine, cannabinoids, or amphetamines in
two standard urine drug screens.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">8 USE IN SPECIFIC POPULATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43684-0"><a name="splSectionPLRPopulations" id=
"splSectionPLRPopulations"></a> <a name="section-9" id=
"section-9"></a>
<div class="Section" data-sectioncode="42228-7"><a name=
"splSectionPLRPregnancy" id="splSectionPLRPregnancy"></a> <a name=
"section-9.1" id="section-9.1"></a>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold Italics">Pregnancy Category
C:</span></p>
<p>There are no adequate and well-controlled studies of Edluar in
pregnant women. Edluar should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus.</p>
<p>Studies to assess the effects on children whose mothers took
zolpidem during pregnancy have not been conducted. There is a
published case report documenting the presence of zolpidem in human
umbilical cord blood. Children born to mothers taking
sedative-hypnotic drugs may be at some risk for withdrawal symptoms
from the drug during the postnatal period. In addition, neonatal
flaccidity has been reported in infants born to mothers who
received sedative-hypnotic drugs during pregnancy.</p>
<p>Administration of zolpidem to pregnant rats and rabbits resulted
in adverse effects on offspring development at doses greater than
the maximum recommended human dose (MRHD) of 10 mg/day (8 mg/day
zolpidem base); however, teratogenicity was not observed.</p>
<p>When zolpidem was administered at oral doses of 4, 20, and 100
mg base/kg (approximately 5, 24, and 120 times the MRHD on a
mg/m<span class="Sup">2</span> basis) to pregnant rats during the
period of organogenesis, dose-related decreases in fetal skull
ossification occurred at all but the lowest dose, which is
approximately 5 times the MRHD on a mg/m<span class="Sup">2</span>
basis. In rabbits treated during organogenesis with zolpidem at
oral doses of 1, 4, and 16 mg base/kg (approximately 2.5, 10, and
40 times the MRHD on a mg/m<span class="Sup">2</span> basis),
increased embryo-fetal death and incomplete fetal skeletal
ossification occurred at the highest dose. The no-effect dose for
embryo-fetal toxicity in rabbits is approximately 10 times the MRHD
on a mg/m<span class="Sup">2</span> basis. Administration of
zolpidem to rats at oral doses of 4, 20, and 100 mg base/kg
(approximately 5, 24, and 120 times the MRHD on a mg/m<span class=
"Sup">2</span> basis) during the latter part of pregnancy and
throughout lactation produced decreased offspring growth and
survival at all but the lowest dose, which is approximately 5 times
the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
</div>
<div class="Section" data-sectioncode="34079-4"><a name=
"splSectionPLRLabor" id="splSectionPLRLabor"></a> <a name=
"section-9.2" id="section-9.2"></a>
<h2>8.2 Labor and delivery</h2>
<p class="First">Edluar has no established use in labor and
delivery <span class="Italics">[see Pregnancy</span> (<span class=
"Underline"><a href=
"#splSectionPLRPregnancy">8.1</a></span>)<span class=
"Italics">].</span></p>
</div>
<div class="Section" data-sectioncode="34080-2"><a name=
"splSectionPLRNursing" id="splSectionPLRNursing"></a> <a name=
"section-9.3" id="section-9.3"></a>
<h2>8.3 Nursing mothers</h2>
<p class="First">Zolpidem is excreted into human milk. Studies in
lactating mothers indicate that the t<span class="Sub">1/2</span>
of zolpidem is similar to that in non-lactating women (2.6 Â± 0.3
hours). The effect of zolpidem on the nursing infant is not known.
Caution should be exercised when Edluar is administered to a
nursing mother.</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name=
"splSectionPLRPediatric" id="splSectionPLRPediatric"></a> <a name=
"section-9.4" id="section-9.4"></a>
<h2>8.4 Pediatric use</h2>
<p class="First">Safety and effectiveness of Edluar have not been
established in pediatric patients below the age of 18.</p>
<p>In an 8-week controlled study, 201 pediatric patients (aged 6-17
years) with insomnia associated with
attention-deficit/hyperactivity disorder (90% of the patients were
using psychoanaleptics) were treated with an oral solution of
zolpidem (n=136), or placebo (n=65). Zolpidem did not significantly
decrease latency to persistent sleep, compared to placebo, as
measured by polysomnography after 4 weeks of treatment. Psychiatric
and nervous system disorders comprised the most frequent (&gt;5%)
treatment-emergent adverse reactions observed with zolpidem versus
placebo and included dizziness (23.5% vs. 1.5%), headache (12.5%
vs. 9.2%), and hallucinations (7.4% vs. 0%) <span class=
"Italics">[see Warnings and Precautions</span> (<span class=
"Underline"><a href="#splSection10">5.6</a></span>)<span class=
"Italics">]</span>. Ten patients on zolpidem (7.4%) discontinued
treatment due to an adverse reaction<span class=
"Italics">.</span></p>
</div>
<div class="Section" data-sectioncode="34082-8"><a name=
"splSectionPLRGeriatric" id="splSectionPLRGeriatric"></a> <a name=
"section-9.5" id="section-9.5"></a>
<h2>8.5 Geriatric use</h2>
<p class="First">A total of 154 patients in U.S. controlled
clinical trials and 897 patients in non-U.S. clinical trials who
received oral zolpidem were â‰¥60 years of age. For a pool of U.S.
patients receiving zolpidem tartrate at doses of â‰¤10 mg or placebo,
there were three adverse events occurring at an incidence of at
least 3% for zolpidem and for which the zolpidem incidence was at
least twice the placebo incidence (i.e., they could be considered
drug-related).</p>
<div class="scrollingtable">
<table width="80%">
<colgroup>
<col align="center" width="33%">
<col align="center" width="33%">
<col align="center" width="33%"></colgroup>
<thead>
<tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">Adverse Event</th>
<th class="Botrule Lrule Rrule" align="center">Zolpidem</th>
<th class="Botrule Lrule Rrule" align="center">Placebo</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="center">Dizziness</td>
<td class="Botrule Lrule Rrule" align="center">3%</td>
<td class="Botrule Lrule Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Drowsiness</td>
<td class="Botrule Lrule Rrule" align="center">5%</td>
<td class="Botrule Lrule Rrule" align="center">2%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center">Diarrhea</td>
<td class="Botrule Lrule Rrule" align="center">3%</td>
<td class="Botrule Lrule Rrule" align="center">1%</td>
</tr>
</tbody>
</table>
</div>
<p>A total of 30/1,959 (1.5%) non-U.S. patients receiving zolpidem
tartrate reported falls, including 28/30 (93%) who were â‰¥70 years
of age. Of these 28 patients, 23 (82%) were receiving zolpidem
doses &gt;10 mg. A total of 24/1,959 (1.2%) non-U.S. patients
receiving zolpidem reported confusion, including 18/24 (75%) who
were â‰¥70 years of age. Of these 18 patients, 14 (78%) were
receiving zolpidem doses &gt;10 mg.</p>
<p>The dose of Edluar in elderly patients is 5 mg to minimize
adverse effects related to impaired motor and/or cognitive
performance and unusual sensitivity to sedative/hypnotic drugs
<span class="Italics">[see Dosage and Administration</span>
(<span class="Underline"><a href=
"#splSectionPLRDosageAdministration">2</a></span>)<span class=
"Italics">, Warnings and Precautions</span> (<span class=
"Underline"><a href=
"#splSectionPLRWarnings">5</a></span>)<span class="Italics">,
Clinical Pharmacology</span> (<span class="Underline"><a href=
"#splSectionPLRClinicalPharm">12</a></span>) <span class=
"Italics">and Clinical Studies</span> (<span class=
"Underline"><a href=
"#splSectionPLRClinicalStudies">14</a></span>)<span class=
"Italics">].</span></p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">9 DRUG ABUSE AND DEPENDENCE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42227-9"><a name="splSectionPLRDrugAbuse" id=
"splSectionPLRDrugAbuse"></a> <a name="section-10" id=
"section-10"></a>
<div class="Section" data-sectioncode="34085-1"><a name=
"splSectionPLRControlled" id="splSectionPLRControlled"></a>
<a name="section-10.1" id="section-10.1"></a>
<h2>9.1 Controlled substance</h2>
<p class="First">Edluar contains the same active substance,
zolpidem tartrate, as zolpidem tartrate oral tablets and is
classified as a Schedule IV controlled substance by federal
regulation.</p>
</div>
<div class="Section" data-sectioncode="34086-9"><a name=
"splSectionPLRAbuse" id="splSectionPLRAbuse"></a> <a name=
"section-10.2" id="section-10.2"></a>
<h2>9.2 Abuse</h2>
<p class="First">Abuse and addiction are separate and distinct from
physical dependence and tolerance. Abuse is characterized by misuse
of the drug for non-medical purposes, often in combination with
other psychoactive substances. Tolerance is a state of adaptation
in which exposure to a drug induces changes that result in a
diminution of one or more of the drug effects over time. Tolerance
may occur to both desired and undesired effects of drugs and may
develop at different rates for different effects.</p>
<p>Addiction is a primary, chronic, neurobiological disease with
genetic, psychosocial, and environmental factors influencing its
development and manifestations. It is characterized by behaviors
that include one or more of the following: impaired control over
drug use, compulsive use, continued use despite harm, and craving.
Drug addiction is a treatable disease, using a multidisciplinary
approach, but relapse is common.</p>
<p>Studies of abuse potential in former drug abusers found that the
effects of single doses of zolpidem tartrate 40 mg were similar,
but not identical, to diazepam 20 mg, while zolpidem tartrate 10 mg
was difficult to distinguish from placebo.</p>
<p>Because persons with a history of addiction to, or abuse of,
drugs or alcohol are at increased risk for misuse, abuse, and
addiction of Edluar, they should be monitored carefully when
receiving Edluar or any other hypnotic.</p>
</div>
<div class="Section" data-sectioncode="34087-7"><a name=
"splSectionPLRDependence" id="splSectionPLRDependence"></a>
<a name="section-10.3" id="section-10.3"></a>
<h2>9.3 Dependence</h2>
<p class="First">Physical dependence is a state of adaptation that
is manifested by a specific withdrawal syndrome that can be
produced by abrupt cessation, rapid dose reduction, decreasing
blood level of the drug, and/or administration of an
antagonist.</p>
<p>Sedative/hypnotics have produced withdrawal signs and symptoms
following abrupt discontinuation. These reported symptoms range
from mild dysphoria and insomnia to a withdrawal syndrome that may
include abdominal and muscle cramps, vomiting, sweating, tremors,
and convulsions. The following adverse events which are considered
to meet the DSM-III-R criteria for uncomplicated sedative/hypnotic
withdrawal were reported during U.S. clinical trials following
placebo substitution occurring within 48 hours following last
zolpidem tartrate treatment: fatigue, nausea, flushing,
lightheadedness, uncontrolled crying, emesis, stomach cramps, panic
attack, nervousness, and abdominal discomfort. These reported
adverse events occurred at an incidence of 1% or less. However,
available data cannot provide a reliable estimate of the incidence,
if any, of dependence during treatment at recommended doses.
Post-marketing reports of abuse, dependence and withdrawal have
been received.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">10 OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name="splSectionPLROverdose" id=
"splSectionPLROverdose"></a> <a name="section-11" id=
"section-11"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection15" id="splSection15"></a> <a name="section-11.1" id=
"section-11.1"></a>
<h2>10.1 Signs and symptoms</h2>
<p class="First">In postmarketing experience of overdose with
zolpidem tartrate alone, or in combination with CNS-depressant
agents, impairment of consciousness ranging from somnolence to
coma, cardiovascular and/or respiratory compromise, and fatal
outcomes have been reported.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection16" id="splSection16"></a> <a name="section-11.2" id=
"section-11.2"></a>
<h2>10.2 Recommended treatment</h2>
<p class="First">Based on data obtained for zolpidem tartrate,
general symptomatic and supportive measures for overdose with
Edluar should be used along with immediate gastric lavage where
appropriate. Intravenous fluids should be administered as needed.
Zolpidem's sedative hypnotic effect was shown to be reduced by
flumazenil and therefore may be useful; however, flumazenil
administration may contribute to the appearance of neurological
symptoms (convulsions). As in all cases of drug overdose,
respiration, pulse, blood pressure, and other appropriate signs
should be monitored and general supportive measures employed.
Hypotension and CNS depression should be monitored and treated by
appropriate medical intervention. Sedating drugs should be withheld
following zolpidem overdosage, even if excitation occurs. The value
of dialysis in the treatment of overdosage has not been determined,
although hemodialysis studies in patients with renal failure
receiving therapeutic doses have demonstrated that zolpidem is not
dialyzable.</p>
<p>As with the management of all overdosage, the possibility of
multiple drug ingestion should be considered. The physician may
wish to consider contacting a poison control center for up-to-date
information on the management of hypnotic drug product
overdosage.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">11 DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name="splSectionPLRDescription" id=
"splSectionPLRDescription"></a> <a name="section-12" id=
"section-12"></a>
<p class="First">Edluar (zolpidem tartrate) sublingual tablet is a
non-benzodiazepine hypnotic of the imidazopyridine class and is
available in 5 mg and 10 mg strength tablets for sublingual
administration.</p>
<p>Chemically, zolpidem tartrate is
N,N,6-trimethyl-2-p-tolylimidazo[1,2-a] pyridine-3-acetamide
L-(+)-tartrate (2:1). It has the following structure:</p>
<div class="Figure"><img src=
"image.cfm?setid=de965605-268a-4479-86f7-84de949cf36f&amp;name=zolpidem-tartrate-01.jpg"
alt="Image from Drug Label Content"></div>
<p>Zolpidem tartrate is a white to off-white crystalline powder
that is sparingly soluble in water, alcohol, and propylene glycol.
It has a molecular weight of 764.88.</p>
<p>Each Edluar tablet includes the following inactive ingredients:
mannitol, colloidal silicon dioxide, silicified microcrystalline
cellulose, croscarmellose sodium, saccharin sodium, and magnesium
stearate.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">12 CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name="splSectionPLRClinicalPharm" id=
"splSectionPLRClinicalPharm"></a> <a name="section-13" id=
"section-13"></a>
<div class="Section" data-sectioncode="43679-0"><a name=
"splSectionPLRMechAction" id="splSectionPLRMechAction"></a>
<a name="section-13.1" id="section-13.1"></a>
<h2>12.1 Mechanism of action</h2>
<p class="First">Zolpidem, the active moiety of zolpidem tartrate,
is a hypnotic agent with a chemical structure unrelated to
benzodiazepines, barbiturates, or other drugs with known hypnotic
properties. It interacts with a GABA-BZ receptor complex and shares
some of the pharmacological properties of the benzodiazepines. In
contrast to the benzodiazepines, which non-selectively bind to and
activate all BZ receptor subtypes, zolpidem <span class=
"Italics">in vitro</span> binds the BZ<span class="Sub">1</span>
receptor preferentially with a high affinity ratio of the
Î±<span class="Sub">1</span>/Î±<span class="Sub">5</span> subunits.
This selective binding of zolpidem on the BZ<span class=
"Sub">1</span> receptor is not absolute, but it may explain the
relative absence of myorelaxant and anticonvulsant effects in
animal studies as well as the preservation of deep sleep (stages 3
and 4) in human studies of zolpidem tartrate at hypnotic doses.</p>
</div>
<div class="Section" data-sectioncode="43682-4"><a name=
"splSectionPLRPharmacokinetics" id=
"splSectionPLRPharmacokinetics"></a> <a name="section-13.2" id=
"section-13.2"></a>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption:</span></p>
<p>Edluar (zolpidem tartrate) sublingual tablet is bioequivalent to
AmbienÂ® tablets (Sanofi-Aventis) with respect to C<span class=
"Sub">max</span> and AUC. Similar to zolpidem tartrate oral
tablets, Edluar sublingual tablet results in a pharmacokinetic
profile characterized by rapid absorption.</p>
<p>Following administration of single 10 mg Edluar, in 18 (18-65
years of age) healthy adult subjects, the mean peak concentration
(C<span class="Sub">max</span>) of zolpidem was 106 ng/mL (range:
52 to 205 ng/ml) occurring at a median time (T<span class=
"Sub">max</span>) of 82 minutes (range: 30-180 min).</p>
<p>A food-effect study in 18 healthy volunteers compared the
pharmacokinetics of Edluar 10 mg when administered while fasting or
within 20 minutes after a high fat meal. The mean AUC and
C<span class="Sub">max</span> were decreased by 20% and 31%,
respectively, while median T<span class="Sub">max</span> was
prolonged by 28% (from 82 to 105 min). The half-life remained
unchanged. These results suggest that, for faster sleep onset,
Edluar should not be administered with or immediately after a
meal.</p>
<p><span class="Italics">Distribution:</span></p>
<p>Based on data obtained with oral zolpidem, the total protein
binding was found to be 92.5 Â± 0.1% and remained constant,
independent of concentration between 40 and 790 ng/mL.</p>
<p><span class="Italics">Metabolism:</span></p>
<p>Based on data obtained with oral zolpidem, zolpidem is converted
to inactive metabolites that are eliminated primarily by renal
excretion.</p>
<p><span class="Italics">Elimination:</span></p>
<p>When Edluar was administered as a single 5 or 10 mg dose in
healthy adult subjects, the mean zolpidem elimination half-life was
2.85 hours (range: 1.57-6.73 hr) and 2.65 hours (range: 1.75 to
3.77 hr) respectively.</p>
<p><span class="Bold Italics">Special populations</span></p>
<p><span class="Italics">Elderly:</span></p>
<p>In the elderly, the dose for Edluar should be 5 mg <span class=
"Italics">[see Warnings and Precautions</span> (<span class=
"Underline"><a href="#splSectionPLRWarnings">5</a></span>)
<span class="Italics">and Dosage and Administration</span>
(<span class="Underline"><a href=
"#splSectionPLRDosageAdministration">2</a></span>)<span class=
"Italics">].</span> This recommendation is based on several studies
with zolpidem tartrate in which the mean C<span class=
"Sub">max</span>, T<span class="Sub">1/2</span>, and AUC were
significantly increased when compared to results in young adults.
In one study of eight elderly subjects (&gt;70 years), the means
for C<span class="Sub">max</span>, T<span class="Sub">1/2</span>,
and AUC significantly increased by 50% (255 vs 384 ng/mL), 32% (2.2
vs 2.9 hr), and 64% (955 vs 1,562 ngÂ·hr/mL), respectively, as
compared to younger adults (20 to 40 years) following a single 20
mg oral dose. Zolpidem did not accumulate in elderly subjects
following nightly oral dosing of 10 mg for 1 week.</p>
<p><span class="Italics">Hepatic impairment:</span></p>
<p>The pharmacokinetics of zolpidem tartrate in eight patients with
chronic hepatic insufficiency were compared to results in healthy
subjects. Following a single 20-mg oral zolpidem tartrate dose,
mean C<span class="Sub">max</span> and AUC were found to be two
times (250 vs 499 ng/mL) and five times (788 vs 4,203 ngÂ·hr/mL)
higher, respectively, in hepatically-compromised patients.
T<span class="Sub">max</span> did not change. The mean half-life in
cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater
than that observed in normals of 2.2 hr (range: 1.6 to 2.4 hr).
Dosing with Edluar should be modified accordingly in patients with
hepatic insufficiency <span class="Italics">[see</span>
<span class="Italics">Dosage and Administration</span>
(<span class="Underline"><a href="#splSection2">2.2</a></span>)
<span class="Italics">and Warnings and</span><span class=
"Italics">Precautions</span> (<span class="Underline"><a href=
"#splSection10">5.6</a></span>)<span class="Italics">]</span>.</p>
<p><span class="Italics">Renal impairment:</span></p>
<p>The pharmacokinetics of zolpidem tartrate were studied in 11
patients with end-stage 4 renal failure (mean Cl<span class=
"Sub">Cr</span> = 6.5 Â± 1.5 mL/min) undergoing hemodialysis three
times a week, who were dosed with zolpidem tartrate 10 mg orally
each day for 14 or 21 days. No statistically significant
differences were observed for C<span class="Sub">max</span>,
T<span class="Sub">max</span>, half-life, and AUC between the first
and last day of drug administration when baseline concentration
adjustments were made. On day 1, C<span class="Sub">max</span> was
172 Â± 29 ng/mL (range: 46 to 344 ng/mL). After repeated dosing for
14 or 21 days, C<span class="Sub">max</span> was 203 Â± 32 ng/mL
(range: 28 to 316 ng/mL). On day 1, T<span class="Sub">max</span>
was 1.7 Â± 0.3 hr (range: 0.5 to 3.0 hr); after repeated dosing
T<span class="Sub">max</span> was 0.8 Â± 0.2 hr (range: 0.5 to 2.0
hr). This variation is accounted for by noting that last-day serum
sampling began 10 hours after the previous dose, rather than after
24 hours. This resulted in residual drug concentration and a
shorter period to reach maximal serum concentration. On day 1,
T<span class="Sub">1/2</span> was 2.4 Â± 0.4 hr (range: 0.4 to 5.1
hr). After repeated dosing, T<span class="Sub">1/2</span> was 2.5 Â±
0.4 hr (range: 0.7 to 4.2 hr). AUC was 796 Â± 159 ngÂ·hr/mL after the
first dose and 818 Â± 170 ngÂ·hr/mL after repeated dosing. Zolpidem
was not hemodialyzable. No accumulation of unchanged drug appeared
after 14 or 21 days. Zolpidem pharmacokinetics were not
significantly different in renally-impaired patients. No dosage
adjustment of Edluar is necessary in patients with compromised
renal function.</p>
<p><span class="Bold Italics">Drug interactions</span></p>
<p><span class="Italics">CNS-active drugs:</span></p>
<p>Since the systematic evaluations of zolpidem in combination with
other CNS-active drugs have been limited, careful consideration
should be given to the pharmacology of any CNS-active drug to be
used with zolpidem. Any drug with CNS-depressant effects could
potentially enhance the CNS-depressant effects of zolpidem.</p>
<p>Zolpidem tartrate was evaluated in healthy volunteers in
single-dose interaction studies for several CNS drugs. Imipramine
in combination with zolpidem produced no pharmacokinetic
interaction other than a 20% decrease in peak levels of imipramine,
but there was an additive effect of decreased alertness. Similarly,
chlorpromazine in combination with zolpidem produced no
pharmacokinetic interaction, but there was an additive effect of
decreased alertness and psychomotor performance.</p>
<p>A study involving haloperidol and zolpidem revealed no effect of
haloperidol on the pharmacokinetics or pharmacodynamics of
zolpidem. The lack of a drug interaction following single-dose
administration does not predict a lack following chronic
administration.</p>
<p>An additive effect on psychomotor performance between alcohol
and oral zolpidem was demonstrated <span class="Italics">[see
Warnings and Precautions: CNS depressant effects</span>
(<span class="Underline"><a href=
"#splSection9">5.5</a></span>)<span class="Italics">].</span></p>
<p>A single-dose interaction study with zolpidem tartrate10 mg and
fluoxetine 20 mg at steady-state levels in male volunteers did not
demonstrate any clinically significant pharmacokinetic or
pharmacodynamic interactions. When multiple doses of zolpidem and
fluoxetine at steady state the concentrations were evaluated in
healthy females, increase in the zolpidem half-life (17%) was
observed. There was no evidence of an additive effect in
psychomotor performance.</p>
<p>Following five consecutive nightly doses of oral zolpidem
tartrate10 mg in the presence of sertraline 50 mg (17 consecutive
daily doses, at 7:00 am, in healthy female volunteers), zolpidem
C<span class="Sub">max</span> was significantly higher (43%) and
T<span class="Sub">max</span> was significantly decreased (53%).
Pharmacokinetics of sertraline and N-desmethylsertraline were
unaffected by zolpidem.</p>
<p><span class="Italics">Drugs that affect drug metabolism via
cytochrome P450:</span></p>
<p>Some compounds known to inhibit CYP3A may increase exposure to
zolpidem. The effect of inhibitors of other P450 enzymes has not
been carefully evaluated.</p>
<p>A randomized, double-blind, crossover interaction study in ten
healthy volunteers between itraconazole (200 mg once daily for 4
days) and a single dose of zolpidem tartrate (10 mg) given 5 hours
after the last dose of itraconazole resulted in a 34% increase in
AUC<span class="Sub">0-âˆž</span> of zolpidem tartrate. There were no
significant pharmacodynamic effects of zolpidem on subjective
drowsiness, postural sway, or psychomotor performance.</p>
<p>A randomized, placebo-controlled, crossover interaction study in
eight healthy female subjects between five consecutive daily doses
of rifampin (600 mg) and a single dose of zolpidem tartrate (20 mg)
given 17 hours after the last dose of rifampin showed significant
reductions of the AUC (73%), C<span class="Sub">max</span> (58%),
and T<span class="Sub">1/2</span> (36 %) of zolpidem together with
significant reductions in the pharmacodynamic effects of zolpidem
tartrate.</p>
<p>A randomized double-blind crossover interaction study in twelve
healthy subjects showed that co-administration of a single 5 mg
dose of zolpidem tartrate with ketoconazole, a potent CYP3A4
inhibitor, given as 200 mg twice daily for 2 days increased Cmax of
zolpidem (30%) and the total AUC of zolpidem (70%) compared to
zolpidem alone and prolonged the elimination half-life (30 %) along
with an increase in the pharmacodynamic effects of zolpidem.
Consideration should be given to using a lower dose of zolpidem
when ketoconazole and zolpidem are given together. Patients should
be advised that use of Edluar with ketoconazole may enhance the
sedative effects.</p>
<p><span class="Italics">Other drugs with no interactions with
zolpidem:</span></p>
<p>A study involving cimetidine/zolpidem tartrate and
ranitidine/zolpidem tartrate combinations revealed no effect of
either drug on the pharmacokinetics or pharmacodynamics of
zolpidem.</p>
<p>Zolpidem tartrate had no effect on digoxin pharmacokinetics and
did not affect prothrombin time when given with warfarin in normal
subjects.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">13 NONCLINICAL TOXICOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"43680-8"><a name="splSectionPLRNonClinical" id=
"splSectionPLRNonClinical"></a> <a name="section-14" id=
"section-14"></a>
<div class="Section" data-sectioncode="34083-6"><a name=
"splSectionPLRPrecautionsCarcinogen" id=
"splSectionPLRPrecautionsCarcinogen"></a> <a name="section-14.1"
id="section-14.1"></a>
<h2>13.1 Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First"><span class=
"Bold Italics">Carcinogenesis:</span></p>
<p>Zolpidem was administered to mice and rats for 2 years at
dietary dosages of 4, 18, and 80 mg base/kg. In mice, these doses
are â‰ˆ2.5, 10, and 50 times the maximum recommended human dose
(MRHD) of 10 mg/day (8 mg zolpidem base) on mg/m<span class=
"Sup">2</span> basis. In rats, these doses are â‰ˆ5, 20, and 100
times the MRHD on a mg/m<span class="Sup">2</span> basis. No
evidence of carcinogenic potential was observed in mice. In rats,
renal tumors (lipoma, liposarcoma) were seen at the mid- and high
doses.</p>
<p><span class="Bold Italics">Mutagenesis:</span></p>
<p>Zolpidem was negative in <span class="Italics">in vitro</span>
(bacterial reverse mutation, mouse lymphoma, and chromosomal
aberration) and <span class="Italics">in vivo</span> (mouse
micronucleus) genetic toxicology assays.</p>
<p><span class="Bold Italics">Impairment of
fertility</span><span class="Bold">:</span></p>
<p>Oral administration of zolpidem (doses of 4, 20, and 100 mg
base/kg or â‰ˆ5, 24, and 120 times the MRHD on a mg/m<span class=
"Sup">2</span> basis) to rats prior to and during mating, and
continuing in females through postpartum day 25, resulted in
irregular estrus cycles and prolonged precoital intervals. The
no-effect dose for these findings is â‰ˆ24 times the MRHD on a
mg/m<span class="Sup">2</span> basis. There was no impairment of
fertility at any dose tested.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">14 CLINICAL STUDIES</a>
<div class="Section toggle-content closed" data-sectioncode=
"34092-7"><a name="splSectionPLRClinicalStudies" id=
"splSectionPLRClinicalStudies"></a> <a name="section-15" id=
"section-15"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection17" id="splSection17"></a> <a name="section-15.1" id=
"section-15.1"></a>
<h2>14.1 Chronic insomnia</h2>
<p class="First">Zolpidem was evaluated in two controlled studies
for the treatment of patients with chronic insomnia (most closely
resembling primary insomnia, as defined in the APA Diagnostic and
Statistical Manual of Mental Disorders, DSM-IVâ„¢). Adult outpatients
with chronic insomnia (n = 75) were evaluated in a double-blind,
parallel group, 5-week trial comparing two doses of zolpidem
tartrate and placebo. On objective (polysomnographic) measures of
sleep latency and sleep efficiency, zolpidem 10 mg was superior to
placebo on sleep latency for the first 4 weeks and on sleep
efficiency for weeks 2 and 4. Zolpidem was comparable to placebo on
number of awakenings at both doses studied.</p>
<p>Adult outpatients (n=141) with chronic insomnia were also
evaluated, in a double-blind, parallel group, 4-week trial
comparing two doses of zolpidem and placebo. Zolpidem 10 mg was
superior to placebo on a subjective measure of sleep latency for
all 4 weeks, and on subjective measures of total sleep time, number
of awakenings, and sleep quality for the first treatment week.</p>
<p>Increased wakefulness during the last third of the night as
measured by polysomnography has not been observed in clinical
trials with zolpidem tartrate.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection18" id="splSection18"></a> <a name="section-15.2" id=
"section-15.2"></a>
<h2>14.2 Transient insomnia</h2>
<p class="First">Normal adults experiencing transient insomnia (n =
462) during the first night in a sleep laboratory were evaluated in
a double-blind, parallel group, single-night trial comparing two
doses of zolpidem tartrate oral tablets (7.5 and 10 mg) and
placebo. Both zolpidem doses were superior to placebo on objective
(polysomnographic) measures of sleep latency, sleep duration, and
number of awakenings.</p>
<p>Normal elderly adults (mean age 68) experiencing transient
insomnia (n = 35) during the first two nights in a sleep laboratory
were evaluated in a double-blind, crossover, 2-night trial
comparing four doses of zolpidem (5, 10, 15 and 20 mg) and placebo.
All zolpidem doses were superior to placebo on the two primary PSG
parameters (sleep latency and efficiency) and all four subjective
outcome measures (sleep duration, sleep latency, number of
awakenings, and sleep quality).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection19" id="splSection19"></a> <a name="section-15.3" id=
"section-15.3"></a>
<h2>14.3 Studies pertinent to safety concerns for sedative/hypnotic
drugs</h2>
<p class="First"><span class="Bold Italics">Next-day residual
effects:</span></p>
<p>Next-day residual effects of zolpidem tartrate were evaluated in
seven studies involving normal subjects. In three studies in adults
(including one study in a phase advance model of transient
insomnia) and in one study in elderly subjects, a small but
statistically significant decrease in performance was observed in
the Digit Symbol Substitution Test (DSST) when compared to placebo.
Studies of zolpidem tartrate in non-elderly patients with insomnia
did not detect evidence of next-day residual effects using the
DSST, the Multiple Sleep Latency Test (MSLT), and patient ratings
of alertness.</p>
<p><span class="Bold Italics">Rebound effects:</span></p>
<p>There was no objective (polysomnographic) evidence of rebound
insomnia at recommended doses seen in studies evaluating sleep on
the nights following discontinuation of zolpidem tartrate. There
was subjective evidence of impaired sleep in the elderly on the
first post-treatment night at doses of zolpidem tartrate above the
recommended elderly dose of 5 mg.</p>
<p><span class="Bold Italics">Memory impairment:</span></p>
<p>Controlled studies in adults utilizing objective measures of
memory yielded no consistent evidence of next-day memory impairment
following the administration of zolpidem tartrate. However, in one
study involving zolpidem doses of 10 and 20 mg, there was a
significant decrease in next-morning recall of information
presented to subjects during peak drug effect (90 minutes
post-dose), i.e., these subjects experienced anterograde amnesia.
There was also subjective evidence from adverse event data for
anterograde amnesia occurring in association with the
administration of zolpidem tartrate, predominantly at doses above
10 mg.</p>
<p><span class="Bold Italics">Effects on sleep stages:</span></p>
<p>In studies that measured the percentage of sleep time spent in
each sleep stage, zolpidem tartrate has generally been shown to
preserve sleep stages. Sleep time spent in stages 3 and 4 (deep
sleep) was found comparable to placebo with only inconsistent,
minor changes in REM (paradoxical) sleep at the recommended
dose.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name="splSectionPLRHowSupplied" id=
"splSectionPLRHowSupplied"></a> <a name="section-16" id=
"section-16"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection20" id="splSection20"></a> <a name="section-16.1" id=
"section-16.1"></a>
<h2>16.1 How supplied</h2>
<p class="First">Edluar is supplied as sublingual tablets in two
dosage strengths. Tablets are not scored.</p>
<p>Edluar 5 mg sublingual tablets are round white tablets,
flat-faced, bevel-edged with debossed <img src=
"image.cfm?setid=de965605-268a-4479-86f7-84de949cf36f&amp;name=zolpidem-tartrate-02.jpg"
alt="Image from Drug Label Content"> on one side and supplied
as:</p>
<p><span class="Bold">NDC Number Size</span></p>
<p>42447-112-01 blister pack of 10</p>
<p>42447-112-03 blister pack of 30</p>
<p>42447-112-10 blister pack of 100</p>
<p>The blister packs consist of aluminum/aluminum Child Resistant
Control (CRC) blisters.</p>
<p>Edluar 10 mg sublingual tablets are round white tablets,
flat-faced, bevel-edged with debossed <img src=
"image.cfm?setid=de965605-268a-4479-86f7-84de949cf36f&amp;name=zolpidem-tartrate-03.jpg"
alt="Image from Drug Label Content"> on one side and supplied
as:</p>
<p><span class="Bold">NDC Number Size</span></p>
<p>42447-122-01 blister pack of 10</p>
<p>42447-122-03 blister pack of 30</p>
<p>42447-122-10 blister pack of 100</p>
<p>The blister packs consist of aluminum/aluminum Child Resistant
Control (CRC) blisters.</p>
</div>
<div class="Section" data-sectioncode="44425-7"><a name=
"splSection21" id="splSection21"></a> <a name="section-16.2" id=
"section-16.2"></a>
<h2>16.2 Storage and handling</h2>
<p class="First">Store at controlled room temperature 20-25Â°C
(68-77Â°F). Protect from light and moisture.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">17 PATIENT COUNSELING INFORMATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34076-0"><a name="splSectionPLRPatientInfo" id=
"splSectionPLRPatientInfo"></a> <a name="section-17" id=
"section-17"></a>
<p class="First">Prescribers or other healthcare professionals
should inform patients, their families, and their caregivers about
the benefits and risks associated with treatment with
sedative-hypnotics, should counsel them in its appropriate use, and
should instruct them to read the accompanying Medication Guide
<span class="Italics">[see Medication Guide</span> (<span class=
"Underline"><a href=
"#splSectionMedguide">17.4</a></span>)<span class=
"Italics">].</span></p>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection22" id="splSection22"></a> <a name="section-17.1" id=
"section-17.1"></a>
<h2>17.1 Severe anaphylactic and anaphylactoid reactions</h2>
<p class="First">Inform patients that severe anaphylactic and
anaphylactoid reactions have occurred with zolpidem. Describe the
signs/symptoms of these reactions and advise patients to seek
medical attention immediately if any of them occur.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection23" id="splSection23"></a> <a name="section-17.2" id=
"section-17.2"></a>
<h2>17.2 Sleep-driving and other complex behaviors</h2>
<p class="First">There have been reports of people getting out of
bed after taking a sedative-hypnotic and driving their cars while
not fully awake, often with no memory of the event. If a patient
experiences such an episode, it should be reported to his or her
doctor immediately, since "sleep-driving" can be dangerous. This
behavior is more likely to occur when Edluar is taken with alcohol
or other central nervous system depressants <span class=
"Italics">[see Warnings and Precautions</span> (<span class=
"Underline"><a href="#splSection7">5.3</a></span>)<span class=
"Italics">].</span> Other complex behaviors (e.g., preparing and
eating food, making phone calls, or having sex) have been reported
in patients who are not fully awake after taking a
sedative-hypnotic. As with "sleep-driving", patients usually do not
remember these events.</p>
<p>In addition, patients should be advised to report all
concomitant medications to the prescriber. Patients should be
instructed to report events such as sleep-driving and other complex
behaviors immediately to the prescriber.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"splSection24" id="splSection24"></a> <a name="section-17.3" id=
"section-17.3"></a>
<h2>17.3 Administration instructions</h2>
<p class="First">Patients should be counseled to take Edluar right
before they get in bed and only when they are able to stay in bed a
full night (7-8 hours) before being active again. Edluar tablets
should not be taken with or immediately after a meal. Advise
patients NOT to take Edluar when drinking alcohol. Edluar
sublingual tablet should be placed under the tongue, where it will
disintegrate. The tablet should not be swallowed and the tablet
should not be taken with water.</p>
</div>
<div class="Section" data-sectioncode="42231-1"><a name=
"splSectionMedguide" id="splSectionMedguide"></a> <a name=
"section-17.4" id="section-17.4"></a>
<h2>17.4 Medication guide</h2>
<p class="First"><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">Edluarâ„¢ [ED'</span>-loo-ahr<span class=
"Bold">]</span></p>
<p>(zolpidem tartrate sublingual tablets)</p>
<p>Read this Medication Guide Edluar before you start taking Edluar
and each time you get a refill. There may be new information. This
Medication Guide does not take the place of talking to your doctor
about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I
should know about Edluar?</span></p>
<p><span class="Bold">After taking Edluar, you may get up out of
bed while not being fully awake and do an activity that you do not
know you are doing. The next morning, you may not remember that you
did anything during the night.</span> You have a higher chance for
doing these activities if you drink alcohol or take other medicines
that make you sleepy with Edluar. Reported activities include:</p>
<ul class="Disc">
<li>driving a car ("sleep-driving")</li>
<li>making and eating food</li>
<li>talking on the phone</li>
<li>having sex</li>
<li>sleep-walking.</li>
</ul>
<p><span class="Bold">Call your doctor right away if you find out
that you have done any of the above activities after taking
Edluar.</span></p>
<p><span class="Bold">Important</span></p>
<p><span class="Bold">Take Edluar exactly as prescribed</span></p>
<ul class="Disc">
<li>Do not take more Edluar than prescribed.</li>
<li>Take Edluar right before you get in bed, not sooner.</li>
</ul>
<p><span class="Bold">Do not take Edluar if you:</span></p>
<ul class="Disc">
<li>drink alcohol</li>
<li>take other medicines that can make you sleepy. Talk to your
doctor about all of your medicines. Your doctor will tell you if
you can take Edluar with your other medicines.</li>
<li>cannot get a full night's sleep</li>
</ul>
<p><span class="Bold">What is Edluar?</span></p>
<p>Edluar is a sedative-hypnotic (sleep) medicine. Edluar is used
in adults for the short-term treatment of a sleep problem called
insomnia. A symptom of insomnia includes:</p>
<ul class="Disc">
<li>trouble falling asleep</li>
</ul>
<p>Edluar is not for children.</p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col align="left" width="100%"></colgroup>
<tbody class="Headless">
<tr class="First Last">
<td class="Botrule Lrule Rrule" align="left">Edluar is a federally
controlled substance (C-IV) because it can be abused or lead to
dependence. Keep Edluar in a safe place to prevent misuse and
abuse. Selling or giving away Edluar may harm others, and is
against the law. Tell your doctor if you have ever abused or been
dependent on alcohol, prescription medicines or street drugs.</td>
</tr>
</tbody>
</table>
</div>
<p><span class="Bold">Who should not take Edluar?</span></p>
<p>Do not take Edluar if you have had an allergic reaction to
zolpidem (AmbienÂ®, Ambien CR<span class="Bold"><span class=
"Sup">â„¢</span></span>, ZolpiMist<span class="Bold"><span class=
"Sup">â„¢</span></span>, Edluar<span class="Bold"><span class=
"Sup">â„¢</span></span>).</p>
<p>Some signs of allergic reaction may be swelling of the face, a
feeling of the throat closing, or difficulty breathing shortly
after taking Zolpidem.</p>
<p>Do not take Edluar if you are allergic to anything in it.</p>
<p>See the end of this Medication Guide for a complete list of
ingredients in Edluar.</p>
<p><span class="Bold">Edluar may not be right for you. Before
starting Edluar, tell your doctor about all of your health
conditions, including if you:</span></p>
<ul class="Disc">
<li>have a history of depression, mental illness or, suicidal
thoughts</li>
<li>have a history of drug or alcohol abuse or addiction</li>
<li>have kidney or liver disease</li>
<li>have lung disease or breathing problems</li>
<li>are pregnant, planning to become pregnant, or
breastfeeding</li>
</ul>
<p>Tell your doctor about all of the medicines you take including
prescription and nonprescription medicines, vitamins and herbal
supplements. Medicines can interact with each other, sometimes
causing serious side effects.</p>
<p><span class="Bold">Do not take Edluar with other medicines that
can make you sleepy.</span></p>
<p>Know the medicines you take. Keep a list of your medicines with
you to show your doctor and pharmacist each time you get a new
medicine.</p>
<p><span class="Bold">How should I take Edluar?</span></p>
<ul class="Disc">
<li>Take Edluar exactly as prescribed. Do not take more Edluar than
prescribed for you<span class="Italics">.</span></li>
<li><span class="Bold">Take Edluar right before you get into
bed.</span></li>
<li><span class="Bold">Do not take Edluar unless you are able to
stay in bed a full night (7-8 hours) before you must be active
again.</span></li>
<li>For faster sleep onset, Edluar should NOT be taken with or
right after a meal.</li>
<li>Do not use the tablet if the seal on the childproof blister
pack is broken, or if the blister holding the tablet is
broken.</li>
<li>To open the blister pack, separate the individual blisters at
the perforations. Peel off the top layer of paper, and push the
tablet through the foil.</li>
<li>Place the tablet under the tongue, where it will disintegrate.
Do not swallow or take with water.</li>
<li>Call your doctor if your insomnia worsens or is not better
within 7 to 10 days. This may mean that there is another condition
causing your sleep problem.</li>
<li>If you take too much Edluar or overdose, call your doctor or
poison control center right away, or get emergency treatment.</li>
</ul>
<p><span class="Bold">What are the possible side effects of
Edluar?</span></p>
<p><span class="Bold">Serious side effects of Edluar
include:</span></p>
<ul class="Disc">
<li><span class="Bold">getting out of bed while not being fully
awake and do an activity that you do not know you are doing.</span>
(See "What is the most important information I should know about
Edluar?")</li>
<li><span class="Bold">abnormal thoughts and behavior</span><br>
Symptoms include more outgoing or aggressive behavior than normal,
confusion, agitation, hallucinations, worsening of depression,
suicidal thoughts or actions.</li>
<li><span class="Bold">memory loss</span></li>
<li><span class="Bold">anxiety</span></li>
<li><span class="Bold">severe allergic reactions</span><br>
Symptoms include swelling of the tongue or throat, trouble
breathing, and nausea and vomiting. Get emergency medical help if
you get these symptoms after taking Edluar.</li>
</ul>
<p><span class="Bold">Call your doctor right away if you have any
of the above side effects or any other side effects that worry you
while using Edluar.</span></p>
<p><span class="Bold">The most common side effects of Edluar
are:</span></p>
<ul class="Disc">
<li>drowsiness</li>
<li>dizziness</li>
<li>diarrhea</li>
<li>"drugged feelings"</li>
<li>fatigue</li>
<li>headache</li>
</ul>
<p>You may still feel drowsy the next day after taking Edluar.</p>
<p><span class="Bold">Do not drive or do any dangerous activities
after taking Edluar until you feel fully awake.</span></p>
<p><span class="Bold">After you stop taking a sleep
medicine</span>, you may have symptoms for 1 to 2 days such as:</p>
<p>trouble sleeping, nausea, flushing, lightheadedness,
uncontrolled crying, vomiting, stomach cramps, panic attack,
nervousness, and stomach area pain</p>
<p>These are not all the side effects of Edluar. Ask your doctor or
pharmacist for more information.</p>
<p>Call your doctor for medical advice about side effects. You may
report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Edluar?</span></p>
<ul class="Disc">
<li>Store Edluar between 68Â° and 77Â°F (20Â° to 25Â°C). Protect from
light and moisture.</li>
<li>Keep Edluar and all medicines out of reach of children.</li>
</ul>
<p><span class="Bold">General Information about Edluar</span></p>
<ul class="Disc">
<li>Medicines are sometimes prescribed for purposes other than
those listed in a Medication Guide.</li>
<li>Do not use Edluar for a condition for which it was not
prescribed.</li>
<li>Do not share Edluar with other people, even if you think they
have the same symptoms that you have. It may harm them and it is
against the law.</li>
</ul>
<p>This Medication Guide summarizes the most important information
about Edluar.</p>
<p>If you would like more information, talk with your doctor. You
can ask your doctor or pharmacist for information about Edluar that
is written for healthcare professionals.</p>
<p>For more information about Edluar, call Meda Pharmaceuticals at
1-800-526-3840.</p>
<p><span class="Bold">What are the ingredients in
Edluar?</span></p>
<p><span class="Bold">Active Ingredient:</span> zolpidem
tartrate</p>
<p><span class="Bold">Inactive Ingredients:</span> mannitol,
colloidal silicon dioxide, silicified microcrystalline cellulose,
croscarmellose sodium, saccharin sodium, and magnesium
stearate.</p>
<p><span class="Bold">Rx Only</span></p>
<p>This Medication Guide has been approved</p>
<p>by U.S. Food and Drug Administration.</p>
<p>Orexo AB, Sweden</p>
<p>March 2009</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>EDLUAR</strong><br>
<span class="contentTableReg">zolpidem tartrate tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42447-112</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem">CIV</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>zolpidem tartrate</strong> (UNII:
WY6W63843K) (zolpidem - UNII:7K383OQI23)</td>
<td class="formItem"></td>
<td class="formItem">5 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong> (UNII:
3OWL53L36A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicified microcrystalline
cellulose</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide, colloidal</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong> (UNII:
M28OL1HH48)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>saccharin sodium</strong> (UNII:
SB8ZUX40TY)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">true</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:42447-112-01</td>
<td class="formItem">10 in 1 BLISTER PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:42447-112-03</td>
<td class="formItem">30 in 1 BLISTER PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">3</th>
<td class="formItem">NDC:42447-112-10</td>
<td class="formItem">100 in 1 BLISTER PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer"></td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>EDLUAR</strong><br>
<span class="contentTableReg">zolpidem tartrate tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42447-122</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem">CIV</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>zolpidem tartrate</strong> (UNII:
WY6W63843K) (zolpidem - UNII:7K383OQI23)</td>
<td class="formItem"></td>
<td class="formItem">10 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong> (UNII:
3OWL53L36A)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicified microcrystalline
cellulose</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide, colloidal</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong> (UNII:
M28OL1HH48)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>saccharin sodium</strong> (UNII:
SB8ZUX40TY)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">true</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:42447-122-01</td>
<td class="formItem">10 in 1 BLISTER PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:42447-122-03</td>
<td class="formItem">30 in 1 BLISTER PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">3</th>
<td class="formItem">NDC:42447-122-10</td>
<td class="formItem">100 in 1 BLISTER PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer"></td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> Meda Pharmaceuticals</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22zolpidem%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=zolpidem"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=zolpidem"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00095&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">EDLUAR- zolpidem tartrate tablet<br></h3>
<h4>Number of versions: 2</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Aug 17, 2009</td>
<td>1 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=11635">download</a></td>
</tr>
<tr>
<td>Apr 21, 2009</td>
<td>1</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=10372">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">EDLUAR- zolpidem tartrate tablet<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=836641">836641</a></td>
<td>zolpidem tartrate 10 MG Sublingual Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=836641">836641</a></td>
<td>Zolpidem tartrate 10 MG Sublingual Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=836645">836645</a></td>
<td>EDLUAR 10 MG Sublingual Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=836645">836645</a></td>
<td>Zolpidem tartrate 10 MG Sublingual Tablet [Edluar]</td>
<td>SBD</td>
</tr>
<tr>
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=836645">836645</a></td>
<td>Edluar 10 MG Sublingual Tablet</td>
<td>SY</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">EDLUAR- zolpidem tartrate tablet<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=de965605-268a-4479-86f7-84de949cf36f"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=de965605-268a-4479-86f7-84de949cf36f</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AEDLUAR%2D%20Zolpidem%20Tartrate%20Tablet%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dde965605%2D268a%2D4479%2D86f7%2D84de949cf36f%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "EDLUAR- zolpidem tartrate tablet <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
